Health policy and systems research (HPSR) is increasingly funded and undertaken as part of health system strengthening efforts worldwide. HPSR ethics is also a relatively new and emerging field, with numerous normative and descriptive questions that have largely not been considered.
Introduction
Health policy and systems research (HPSR) is increasingly funded as part of health system strengthening efforts worldwide (Bennett et al. 2008) . HPSR has been defined as 'a search for knowledge which contributes to health systems strengthening and our understanding of health systems' (Hoffman et al. 2012) . It is an evolving field, whose boundaries, definitions and characteristics are still being discussed and debated (Bennett et al. 2011; Sheikh et al. 2011; Gilson 2012) . However, consensus is emerging that the field is defined by the questions it asks, which are united in their focus on understanding how health systems operate, what needs to be done to improve their performance and how to influence policy to strengthen health systems (Gilson 2012) . These research questions can focus on the hardware aspects (financing, information technology, service delivery, human resources and governance) or software aspects (norms, values and power relations) of health systems . As such, HPSR is seen to encompass or overlap with other types of research (that also overlap with one another), including comparative effectiveness research (CER), health services research, operational research, implementation research and activities (that may or may not be research) like quality improvement (QI) (Gilson 2012; Hoffman et al. 2012) . Definitions of these fields are provided in Box 1.
Health systems software is fundamentally related to ethics. The values reflected in the performance goals set for health systems correspond to underlying ethical theories (Roberts et al. 2004) . For example, egalitarian commitments are at the core of national health system goals that include both financial risk protection and equal access to health services for the most disadvantaged groups within society (Roberts et al. 2004) . HPSR can, therefore, play a role in promoting certain values by generating new knowledge to advance particular health systems goals. This in itself reflects an ethical consideration when designing HPSR studies.
HPSR ethics is also a relatively new and emerging field. Ethics too has both hardware and software components that find expression at various levels (international, national, local and institutional) . Hardware components may include ethics guidelines and policies, ethics committees, ethics personnel, ethics training initiatives and the like. Software components include agreed upon ethical principles and values and processes to honor and uphold these values such as informed consent and community engagement. Ideally, ethics software components should be reflected in its hardware components.
Research questions in ethics can be normative or descriptive (Mathews et al. 2016) . So far, the question of what values and principles should guide HPSR ethics has received little attention. Do traditional biomedical research ethics principles apply to HPSRnamely autonomy, beneficence and justice? Recent work on ethical principles to guide health systems suggests that the core values and principles for HPSR may be broader than the traditional principles, including, for example, principles such as public engagement and sustainability (Krubiner and Hyder 2014) . What these principles might mean in the context of HPSR has not yet been explored.
This scoping review is, however, not itself a normative contribution. It does not aim to propose or argue for what core ethical principles and values should guide HPSR, though the importance of such work is emphasized. Instead, the scoping review has a descriptive and analytic function. It seeks to provide an overview of what ethical issues have emerged in relation to HPSR and what guidance exists on how to address them in order to inform ongoing efforts to develop meaningful and comprehensive ethics guidance for HPSR practice. HPSR differs from classic biomedical research in multiple important ways, including its aims, the methods it uses, the nature of interventions under evaluation and the research participants targeted by studies. It has been argued that the ethical issues arising in HPSR projects may, therefore, be unique or nuanced relative to biomedical research (Hyder et al. 2014a) .
HPSR differs from traditional biomedical research 1 in that it seeks to understand health systems in a real-world context (as opposed to measuring intervention efficacy under ideal conditions) and is commonly embedded in healthcare practice. Such research relies on a wide range of methods that span both the relativist and positivist traditions such as cluster trials, records review, observational studies, participatory action research, case studies, surveys and economic evaluations. Its methods and interventions are frequently iterative and dynamic, changing over the course of projects, which is not a common feature of explanatory randomizedcontrolled clinical trials. HPSR often tests interventions at the population or group level rather than the individual level. Unlike drugs or vaccines, these interventions are directed at changing health systems rather than individuals' physiology and include novel health delivery mechanisms for existing services, methods of creating demand for existing services, or human resource management strategies for clinics or hospitals (Hyder et al. 2014a) . HPSR can also be exploratory and descriptive (Gilson 2012) . These features may raise ethical concerns that differ from those arising in biomedical research. For example, where HPSR tests financial incentives to promote healthy behaviors (e.g. use of health Box 1. Examples of approaches encompassed by HPSR Quality improvement (QI) aims to improve the quality and/or efficiency of health care and service delivery systems in health organizations. QI usually has a more internal (or bottom up) perspective addressing what kind of approaches actors within the organization themselves can utilize to improve quality of care (Hoffman et al. 2012) . The aim of QI is typically to improve a system or organization as a means to improving individual outcomes. Thus, the focus is on system functioning rather than the individual.
Comparative effectiveness research (CER) aims to compare one treatment for a condition or health service against another to determine what works best for different individuals (Vaida 2016) .
Operational research aims to solve operational issues that arise in health programs and organizations (Remme 2010 ). It can include many different research methods and generally seeks to develop approaches to improve the practical performance of programs, initiatives and/or service delivery.
Implementation research aims to systematically identify how best to deliver health interventions and services in real-world contexts (Peters et al. 2013) . It is closely related to operations research, but its focus is usually broader than a specific program or organization.
Health services research examines healthcare at the organizational level (e.g. clinics and hospitals). It aims to improve the delivery of health services and has multiple sub-disciplines that include but are not limited to the four listed above (Hoffman et al. 2012) . services), pertinent ethical considerations relate to obtaining authorization at the population level, determining how to appropriately weigh the benefits of the incentive provided in relation to anticipated risks and assessing the incentive's impact on the distribution of opportunities in the host population (e.g. are existing social inequalities exacerbated). Common concerns about incentives creating 'undue inducement', which arise in biomedical research, may be misplaced when recipients generally regard the incentivized behaviors as worthwhile or beneficial (London et al. 2012) .
A small but growing body of scholarly work characterizes the various ethics issues inherent to HPSR. Yet no previous scholarship has canvassed the available literature to catalogue the range of ethical issues arising in HPSR or assessed whether that literature captures all relevant issues. Beyond this, no formal guidance document exists to clarify what funders, researchers, institutions and research ethics committees (RECs) must do to address or review the ethical issues inherent in HPSR. Currently available research ethics guidelines focus predominantly on traditional forms of health research, including biomedical, social science and epidemiological research. There is no equivalent of the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines for Biomedical Research Involving Human Subjects for HPSR. As a result, funders, researchers, institutions and RECs worldwide struggle, first, to identify what ethical issues are inherent in HPSR projects and second, to interpret and apply ethical principles to the increasing number of HPSR studies being performed globally. Applying existing guidelines for other types of health research to HPSR can be fraught with difficulty. The example of financial incentive studies clearly demonstrates how traditional approaches to thinking about incentives in research as a potential threat to autonomy do not neatly align with certain HPSR projects. Application of these approaches can sometimes lead RECs to make 'poor decisions' that can impede the conduct of HPSR projects (London et al. 2012) .
Towards the development of much-needed ethics guidance for HPSR, a scoping review of existing formal and grey literature on HPSR ethics was commissioned by the Alliance for Health Policy and Systems Research (the Alliance) at the World Health Organization. The scoping review's primary aims were to identify the range of ethics issues relevant to the conduct of HPSR-with a deliberate (though not exclusive) focus on low-and middle-income country (LMIC) settings-and to describe existing guidance on the key ethics issues relevant to HPSR. The intention was to determine where HPSR-specific guidance exists and where the main gaps in guidance lie in order to direct future ethics scholarship on HPSR. This paper describes the methods and findings of the scoping review. It characterizes the central ethics issues in HPSR identified in the literature, reviews available scholarly and professional guidance and makes recommendations for addressing gaps in existing guidance. The section reviewing existing guidance returns to each of the central ethics issues in HPSR, providing further discussion of their implications and suggestions on how to address them. This scoping review can contribute to more normative questions of HPSR ethics by providing an initial sense of what ethical principles might appropriately apply to HPSR practice in light of the ethical concerns that arise.
Methods

Literature review
Formal literature
To conduct the formal literature review, four categories of search terms were used: HPSR terms, ethics terms (includes Institutional Review Board terms), methods terms and LMIC terms. Three separate systematic literature reviews were conducted, each employing different combinations of the search terms: HPSR terms AND ethics terms AND methods terms; HPSR terms AND ethics terms AND LMIC terms; and methods terms AND ethics terms AND LMIC terms.
The search terms for HPSR, methods, ethics and LMICs were developed through an iterative process, where combinations of controlled vocabulary and key words were piloted in PubMed. Results were assessed for inclusion of a known set of representative literature (i.e. a list of 15 key articles on HPSR ethics). This process resulted in the selection of controlled vocabulary and key words that were included in a search strategy. This search strategy was developed in consultation with bioethicists, health systems researchers and informatics experts at the Johns Hopkins Berman Institute of Bioethics and Bloomberg School of Public Health, and the Kenya Medical Research Institute. The Alliance and two independent reviewers provided comments on the search strategy, which was revised and finalized based on their feedback. The HPSR terms used in this review were designed to capture the wide range of labels applied to research that may be classified as HPSR. They encompassed the following types of research: health systems research, health policy research, health services research, implementation research, operational research and activities that aim to improve the quality and/or efficiency of health service delivery systems such as QI, CER, patient safety research and pragmatic trials. Ethics terms included autonomy, consent, risk, harm, benefit, privacy, vulnerability, justice, equity, community engagement, institutional review board, REC and related terms. Methods terms included cluster trial, observational research, records review, case study, ethnography, economic evaluation, network analysis, participatory action research and variations thereon. The detailed search strategy is available upon request.
The following databases were searched in all languages for articles published between 1 January 1990 and 1 April 2015: PubMed's Medline (1946-present) , Embase (1974 -Present), Global Health (1973 , Scopus (1966-present) , WHO Global Health Regional Libraries (1970-present) and LILACs (1982-present) .
Citations and abstracts were uploaded into Microsoft Excel and deduplicated.
In total, 10 519 citations were identified in the formal literature after de-duplication between the three searches ( Figure 1 ).
Grey literature
Searches of the web were performed using search engines such as OpenDOAR and Bielefeld Academic Search Engine (BASE) to identify other potentially relevant materials. For these searches, the following four sets of terms were searched, resulting in 543 records (OpenDOAR: 158 and BASE: 385): ethics AND health systems research; ethics AND implementation research; ethics AND health services research; and ethics AND operational research.
The following databases were also searched-the US Office for Human Research Protections' International Compilation of Human Research Standards (2012), the Council on Health Research for Development (COHRED) and the Global Ethics Observatory (GEObs)-but did not return relevant materials.
Inclusion criteria
Of the 11 062 articles identified by the formal and grey literature searches, we included only those articles that: described an ethical issue in HPSR or how it might be addressed; described an ethical issue related to a method used in HPSR or how it might be addressed; described how RECs review or should review HPSR (approaches, criteria); described documented difficulties encountered by RECs in the review of HPSR or by researchers seeking REC approval for HPSR studies; or described how laws, ethics guidelines, or regulations apply to HPSR.
We excluded articles and grey literature that described ethical issues and guidance relevant to health sector reform if they did not also raise considerations specifically about research or evaluation of reform efforts.
Literature screening
All titles and abstracts relevant to the study (n ¼ 11 062) underwent dual review to determine whether they met inclusion criteria. Where articles were identified to meet an inclusion criterion by only one of the two reviewers, a third reviewer served as a tie breaker. In total, 126 articles from the formal literature and 37 documents from the grey literature were identified that met one or more of the inclusion criteria (Figure 1 ).
These 163 articles were retrieved and full-text versions were further assessed for eligibility; 54 articles (25 formal and 29 informal) were subsequently excluded because they did not meet any of the inclusion criteria. We further excluded articles not written in English from full text review (n ¼ 2).
Thematic analysis
The 107 full-text articles that met at least one eligibility criterion were thematically analysed using the approach described by Braun and Clarke (2006) . That approach involves the following main steps: (1) familiarization with the data, (2) generating a coding framework, (3) searching for categories and sub-categories and (4) reviewing categories and sub-categories. A coding framework was developed relying on both a priori and emergent categories and subcategories (Ali et al. 2014) . The five main categories were: (1) ethical issues in HPSR, (2) guidance from scholars on how to address ethical issues in HPSR, (3) guidance for RECs and governing bodies on how to address ethical issues in HPSR, (4) experiences with REC review of HPSR protocols and (5) vignettes of core ethics issues or ethical review challenges in HPSR. Each had several sub-categories.
Coding of full-text articles was performed individually by two research assistants using NVivo Version 10. To ensure inter-coder reliability, the project manager oriented each research assistant to the coding framework. Together they used it to code one article in order to promote the research assistants' understanding of how the different categories were defined and how to correctly apply them. Additionally, the project manager reviewed 5% of coded articles, including the first two articles coded by each research assistant. Feedback was provided and discussed. In general, there was high consistency between the project manager and research assistants' coding of full-text articles. Data extracts coded under the five main categories were compiled and analysed by the research team. The project manager checked accuracy of all coded segments.
Results
This section is presented in three parts. First, characteristics of the literature identified by the review are described. Second, key ethical issues discussed in the HPSR literature are detailed. Finally, available guidance is summarized.
Characteristics of relevant literature
Where articles focused on a specific type of HPSR, the most common were QI and CER, health services research and health systems research (Table 1) . Here, the classification of the type of HPSR was based on the specific terminology used in the documents by their authors. Where articles discussed a particular methodological approach, the most common was cluster trials. The majority of documents were published between 2010 and 2015 and only a quarter of articles discussed the ethics of HPSR in LMIC contexts (Table 1) .
Ethical issues in HPSR
Ethical issues in four main categories were identified through thematic analysis of the formal and informal literature: (1) upholding autonomy, (2) identifying and balancing risks and benefits, (3) justice and (4) determination of ethical review requirements. Specific ethical issues in each category are discussed below. These issues were raised in the literature either as questions that bear consideration or as specific ethical concerns.
Upholding autonomy
Identifying multiple types and levels of participants Determining who the research participants are in HPSR studies has been identified as a key challenge (Hutton 2001; Mcrae et al. 2011b; WHO 2013; Hyder et al. 2014a ). This, in part, eventuates because the units of intervention and observation are often not the same. Hyder et al. (2014a) provide the example of an HPSR study where hospitals introduce quality assessment activities for infection control by teams of health providers (unit of intervention), but outcome data are collected on hospital-acquired infections among admitted patients (unit of observation) (Hyder et al. 2014a ). This raises important considerations for informed consent in HPSR, i.e. who are the units of observation and data collection in a given study, are they both considered research participants and should they both be involved in the informed consent process? If so, what information should they each receive in the consent process?
Group level interventions
A distinction is raised in the literature, particularly in the context of cluster trials, between HPSR studies testing interventions that are given to individuals, such as malaria bed nets, or interventions that are distributed at the population-level such as adjustments to standard services offered at public health facilities (Edwards et al. 1999; Hutton 2001; Osrin et al. 2009; Gallo et al. 2012; Taljaard et al. 2013) . The terms 'individual-cluster trial' and 'cluster-cluster trial' have been used to distinguish between the two. Concern has been raised that individual autonomy can be particularly difficult to uphold in cluster-cluster trials. Where group or population-level interventions are tested, it may be difficult for individuals to avoid being exposed to them and they may be unable to meaningfully refuse to participate, opt-out or withdraw from studies (Hundley et al. 2010; Mcrae et al. 2011a; Gallo et al. 2012; Hyder et al. 2014a ). This would occur, for example, where an intervention consisted of enacting a new clinic or hospital policy for performance-based management of health workers. Short of attending a different clinic or hospital outside the cluster, individuals would not be able to avoid being treated by doctors and nurses whose provision of care was guided by the new incentive structure. When research populations of HPSR are large, it may also be impracticable to obtain individual informed consent from participants (Mcrae et al. 2011a; Gallo et al. 2012) . Doing so would entail obtaining the consent of potentially hundreds of thousands of people (e.g. entire districts or cities).
Reliance on gatekeepers or waivers of consent have each been proposed as ways to navigate this particular ethical concern. Yet, both recommendations bring with them a range of additional ethical challenges. Gatekeepers may include (amongst others) locally practicing physicians, a managing partner of a primary care practice or hospital administrative leadership (Anderson et al. 2015) . It has been suggested gatekeepers should play an important role in permitting researchers to enroll clusters in studies (Edwards et al. 1999; Hutton, 2001; Osrin et al. 2009; Taljaard et al. 2013; Hyder et al. 2014a; Anderson et al. 2015) . Gatekeepers, however, may have significant conflicts of interest and it may be difficult to assess their legitimacy (Osrin et al. 2009; Anderson et al. 2015) . Osrin et al. (2009, p. 774) provide the following example, stating:
The Ekjut intervention in Jharkhand, India tries to help women in underserved communities to take charge of their health needs. The process itself raises (at least conceptual) notions of empowerment and agency that could be seen as socio-politically destabilizing. . . . More provocatively, how ethical is it to take consent from (mostly male) guardians who embody the social structure within which the [female] participants will be maneuvering?
When the intervention under study aims to change the status quo, which is common in participatory action research, individuals who represent the traditional power structures and authorities within communities may be a poor choice of gatekeeper. Such individuals will often have conflicts of interest and may not legitimately represent the interests of minorities in their communities. The selection of appropriate gatekeepers is, therefore, a key ethical consideration in cluster-cluster trials.
Others note that waivers of individual consent, when permitted by law or policy, may ethically apply to many HPSR studies that assess group-level interventions Taljaard et al. 2013; Hyder et al. 2014a) . Even so, this strategy raises additional ethical questions such as what constitutes 'minimal risk' in HPSR, as this concept is often essential to waiver determinations. HPSR studies often involve multiple levels of participants, spanning both individuals and groups. A concept of minimal risk in HPSR then encompasses both individual and group risk, but standards-particularly for minimal group risk-have not been defined (Hyder et al. 2014a; Anderson et al. 2015) .
In HPSR studies where individual informed consent is rendered meaningless (i.e. intervention exposure cannot be avoided), impossible to obtain, or waived, should participants, nonetheless, be informed that the study is taking place and, if so, what information should they be given? Should individuals be told simply what the aims of the study are and what kind of intervention is being tested or should they also be fully informed (to the extent it is possible) about the potential risks and benefits associated with the intervention under evaluation? Should steps be taken to ensure that people, especially members of vulnerable groups, have an available means of opting out (Hyder et al. 2014a ; WHO 2013)?
Individual-level interventions
Where individual-level interventions are tested, a number of distinct ethical issues relating to autonomy have been raised. First, should gatekeeper consent be sought prior to directly approaching individuals within a cluster to obtain their consent? If so, is individual consent always necessary under circumstances where a gatekeeper's consent has been obtained (Hyder et al. 2014a; Anderson et al. 2015) ? Second, is individual consent to randomize always required and, if not, what information must be disclosed to participants? This latter question stems from the fact that, in cluster trials, someone with authority to act on behalf of the cluster (a gatekeeper) often makes the decision for the cluster to be randomized (Hundley et al. 2010) . Randomization then occurs before it is possible to approach individual cluster members for informed consent (Hutton 2001; Mcrae et al. 2011a; Gallo et al. 2012 ). Third, is it ethically acceptable for the consent process to vary for participants in experimental vs control groups? Campbell (2000) raises the issue of whether it is necessary to inform individuals in control groups that studies are going on and/or to obtain their informed consent in studies where they receive 'usual care'.
Incentive interventions
Incentive interventions such as conditional cash transfer schemes are common interventions in HPSR (London et al. 2012 ). Yet, in biomedical research, concern exists that attractive incentives may serve as an undue inducement to participate in research. Incentives are sometimes viewed as capable of reducing individual autonomy. Such concerns, however, may deter approval of HPSR testing incentive interventions that seek to be autonomy-promoting (London et al. 2012) .
Quality improvement
Questions have been raised as to whether informed consent may be ethically required for some QI activities, particularly when they involve vulnerable participants such as palliative care patients (Daly and Rosenfeld 2003; Kass and Pronovost 2011) . Often, individual consent is not sought for QI.
Identifying and balancing risks and benefits
The literature suggests a lack of clarity exists about whose risks and benefits should be assessed as part of risk-benefit assessments in HPSR. HPSR studies often have multiple levels of research 'participants', some of whom are not necessarily individuals per se. Since HPSR can generate risks and benefits to individuals, populations or groups and health systems, ethics review may need to account for these additional layers of risk and benefit. Identifying the risks and benefits that can accrue to vulnerable and disadvantaged groups within a research population may require special consideration.
The nature, frequency and severity of potential risks in HPSR are also relatively unknown (Fox and Tulsky 2005) . The various individual and collective risks described in the literature are listed in Table 3 . These risks may be amplified for participants who are vulnerable due to disadvantage and deprivation. Specific risks are identified to arise when particular interventions or methods are used in HPSR.
2 Hyder et al. (2014a) and Molyneux et al. (2009) further argue that the risks associated with HPSR may often be obscure, downstream and hard to anticipate due to limited understanding of how health systems function. If an intervention, for example, involves changing the financing structure of a national insurance scheme, it may have effects on other aspects of the health system such as human resources, governance or service delivery.
There is much less description of possible benefits of HPSR in the ethics literature. Hyder et al. (2014a) state that there may be a broader array of benefits to consider in HPSR relative to biomedical research such as improvements to the health system, provision of health services and health worker capacity-building. Thomson et al. (2014) identify the potential for individual and collective benefits in incentive interventions studies such as enhancing individual autonomy and well-being, improving the quality of relationships, reducing health disparities and strengthening the health system.
Additional ethical considerations raised in the literature include the need to further specify the protections that must be in place to reduce or minimize risks of HPSR studies and how to balance risks and benefits between various participants in HPSR. As HPSR may involve risks and benefits to individuals, groups and/or health systems, future guidance may seek to clarify how risks to individuals might be weighed against risks/benefits to groups and/or health systems and under what circumstances risks to groups and/or health systems can outweigh benefits to individuals.
Justice
HPSR and social justice
The literature affirms that HPSR should help reduce health disparities between and within countries (Levy et al. 2009; Faden et al. 2013b; Pratt 2014) . HPSR is intended to help modify the organization of basic social structures (health systems) in order to improve their performance and is, thus, fundamentally related to broader conditions of social justice. However, concern has been raised that HPSR studies may not be optimally structured to advance this goal. Conceptual and empirical work is needed to identify what features are required for HPSR to promote health justice and/or social justice and to assess whether these features are achieved in practice (Pratt 2014) .
Fair subject selection
In biomedical research, the concept of fair subject selection requires that the selection of participants in research be driven first by the scientific goals of the study, that vulnerable groups not be targeted for risky research and that well-off populations not be targeted for beneficial research (Emanuel et al. 2000) . The role of HPSR in contributing to the reduction of health disparities may have implications for fair subject selection, particularly in the LMIC context. Hyder et al. (2014a, 33) state that 'many HSR studies, especially in LMIC, are in fact conducted with the primary aim of reaching vulnerable groups and providing access to existing or proven interventions for those communities.' Thus, fair subject selection in HPSR may go further than refraining from targeting vulnerable populations for risky research and instead require giving some degree of priority to selecting vulnerable groups as the focus of such equity-oriented studies, but to what degree is unclear.
A related ethical consideration for HPSR in general is ensuring that the research population includes (members of) vulnerable groups (Meyers and Andresen 2000; Hunt et al. 2014) . The evaluation of health system changes often requires the near-universal participation of patients using a service if it is to provide valid information. Yet participants in HPSR may be representative of a limited privileged subset of the population who will be affected by service changes. According to Cassell and Young (2002, p. 316) , '[w] here HPSR contributes to the planning of services and policymaking, the voice of the socially excluded may be muffled and that of the better educated and materially secure, artificially amplified.' This means studies may prove interventions are effective for betteroff segments of society but fail to determine whether they work for disadvantaged groups. Gatekeepers, inappropriate consent requirements and reliance on letters and advertisements to invite individuals to opt-in to HPSR may serve to exclude disadvantaged and vulnerable populations. Other barriers to their inclusion are: illiteracy, the fear of authorities, cost of travel, poor health and having less secure jobs (Cassell and Young 2002; Smith 2008; Hunt et al. 2014) .
Responsiveness
Concern is expressed that HPSR priority-setting is largely a donordriven process that crowds out studies that are responsive to the needs and priorities of host countries (Tapp et al. 2009; Pratt and Hyder 2015a) . Current funding mechanisms may favour HPSR on service delivery and scale up of interventions that support the achievement of global targets (Millennium Development Goals and universal health coverage), rather than HPSR that is responsive to local needs (Pratt and Hyder 2015a) .
Another ethical concern related to responsiveness in HPSR is that, so far, the concept has been applied primarily to biomedical needs and outcomes. It requires research questions to address a health condition or disease within the selected host community or country. Given that HPSR is not a disease-driven field, this understanding of responsiveness may not be appropriate (Pratt and Hyder 2015c) .
Standard of care
A question posed repeatedly in the literature is: what 'standard of care' is owed to control groups and others in HPSR studies (Hill 2004; Kukla 2007; Osrin et al. 2009; Binik et al. 2011; Hyder et al. 2014a) ? Binik et al. (2011) voice the concern that the risks of participating in the control group of a HPSR study, which receives either no intervention or an intervention that is perceived to be suboptimal based on high-income country standards, may not stand in reasonable relation to the potential benefits of participation. However, Osrin et al. (2009, p. 777) note that HPSR interventions may be conceptually different if what we are trying to do is improve the general quality and uptake of care in a situation of vulnerability, limited resources, inequity and system weaknesses. It makes little sense to test an improvement in a system against the best possible version of the existing system, since that is precisely where the problem lies.
Other ethical questions raised relate to the standard of care owed when particular types of HPSR interventions are tested. For instance, Hyder et al. (2014b) query, where HPSR studies assess new service delivery methods for existing effective services, are control groups owed access to the services known to be effective? In this situation, equipoise 3 exists for the delivery method but not for the services delivered through them.
Ancillary care
Limited literature addresses the topic of ancillary care in HPSR. However, ethical questions raised include whether ancillary care obligations apply in HPSR, particularly when conducted in LMIC contexts (e.g. individuals, groups)? If so, who bears these responsibilities and to whom are they owed? Olson (2014) and Hunt et al. (2014) also query whether a broader concept of ancillary care is appropriate for HPSR relative to biomedical research, suggesting that ancillary care in HPSR might properly address systemic health needs or individual needs beyond health.
Research capacity strengthening Very little literature addresses the topic of research capacity strengthening in HPSR. However, one ethical concern raised is that funding for HPSR capacity-building in LMICs does not strongly support interventions that target the systems level. This means that few capacity-building efforts help develop national research systems in LMICs that set HPSR priorities, generate financing for such research, establish networks between research organizations and create links between researchers and decision-makers in health systems (Pratt and Hyder 2015a) . Another ethical concern discussed is that capacitybuilding efforts may not be structured to effectively build LMIC researchers independent research capacity, as training programs (particularly short-courses) are the most commonly used capacity development strategy for HPSR in LMICs (Pratt and Hyder 2015a ).
4
Exploitation Ethical concern about whether study risks are borne primarily by vulnerable and disadvantaged populations while the benefits accrue to more advantaged populations within LMICs and/or external researchers and funders is highlighted in the literature (London et al. 2012; Hyder et al. 2014a ). Dowdy (2006) notes that exploitation can also occur within research partnerships in HPSR. The role of unequal power structures in facilitating exploitation and unfair sharing of benefits is emphasized (Dowdy 2006; White 2009 ).
Post-research commitments
The nature of post-research commitments in HPSR is discussed in the context of dissemination of findings, post-study access to interventions and the translation of research findings into policy and practice. It has been suggested that HPSR researchers have an ethical obligation to disseminate their findings (Davison et al. 2013) . This raises several ethical questions such as how findings should be disseminated and to whom. Due to the frequent practice of aggregating and analyzing data either at the central level within countries or outside of countries, in many instances, [l] ocal government ownership of data may be lost as a resultthe results may be reported in internal donor reports, commercial considerations may block broader dissemination of findings, and the extent of critical analysis or debate is often limited. Donors have been known to circumscribe the distribution of findings that have financial implications for them, or that reflect poorly on project performance. (Hill 2004 , p. 149) Garland et al. (2008) also note that researchers and community partners may not always agree on the dissemination process or venue. Tensions may emerge when disseminated findings are critical of community partners and the health services they provide.
While the issue of post-study access is not unique to HPSR, questions are raised such as: is post-study access to beneficial services or interventions owed in HPSR? If so, to whom (e.g. all levels of participants) and who is obligated to provide access to these interventions (London et al. 2012; Hyder et al. 2014a) ? Another ethical concern is the well-documented lag in, or absence of, research to policy translation. A key feature of HPSR is securing direct instrumental value by supporting changes in policy and practice. Yet a sizeable gap exists in the real world between the evidence generated by HPSR and its use in policy and practice (Pratt and Hyder 2015a) .
Sustainability
Innovations that are relevant to health systems and policy, like innovations in health care generally, are challenging to sustain after the initial study period (Davison et al. 2013; Pratt and Hyder 2015a) . In incentive studies, sustainability may also be relevant to the consideration of potential risks, as introducing and removing incentives for certain behaviors or activities may be harmful if people alter their behaviors and then the intervention is removed (London et al. 2012 ).
Determination of ethical review requirements
The fact that the lines between research and activities like QI, CER and monitoring and evaluation (M&E) are blurry is emphasized in the literature (Horsfall and Cleary 2002; Hill 2004; Chaney et al. 2008; Nerenz 2009; Faden et al. 2013b; Macklin 2014) . Debate continues over whether QI or some forms of QI should be considered research and/or be subject to ethical review (Chaney et al. 2008; Tapp et al. 2009; Taylor et al. 2010; Macklin 2014) . It is unclear what criteria such activities must meet to be considered research, e.g. production of generalizable knowledge, randomization and/or use of particular methods. Fox and Tulsky (2005) suggest that QI activities can have more than one purpose, with a single project designed both to improve health care operations in a particular setting as well as to produce knowledge that can be applied in other settings. It was reported that the current norm, where QI is typically not subject to review by RECs, incentivizes 'gaming the system'-namely, designating projects as QI in order to avoid their having to undergo review (Fox and Tulsky 2005; Horsfall and Cleary 2002) .
In terms of researchers' experiences with REC review of HPSR, four main categories of challenges are described: (1) identifying appropriate bodies for ethics review of HPSR, (2) REC members lacking familiarity with HPSR and the methods it uses, (3) accounting for the flexible, dynamic nature of some forms of HPSR and (4) variation in REC decisions across sites (Ginzler et al. 1990; Jamrozik and Kolybaba 1999; Tod et al. 2002; Daly and Rosenfeld 2003; Hill 2004; Dzjak et al. 2005; Gold and Dewa 2005; Weisbaum et al. 2005; Green et al. 2006; Meslin 2006; Appleton et al. 2007; Cook et al. 2007; Meenaghan et al. 2007; Chaney et al. 2008; Driscoll et al. 2008; Van Teijlingen et al. 2008; Hutton et al. 2008; Mcdonach et al. 2009; Nerenz 2009; Taljaard et al. 2009 Taljaard et al. , 2014 Osrin et al. 2009; Edwards et al. 2012; Petersen et al. 2012; Davis and Chew 2013; Webster and Temple-Smit 2013) . The latter is by far the most frequently discussed in the literature. For example, Edwards et al. (2012) report varying decisions from regulatory bodies in different countries (Romania, Finland, Denmark) as to whether formal ethical review was necessary for a health policy research project involving review of policy documents, data collection through surveys and interviews and observations with policy stakeholders. Additionally, the literature does not report any documented approaches and criteria for REC review of HPSR.
Other issues
Community engagement Ethical concerns about community engagement are discussed primarily in relation to HPSR using participatory action methods (Davison et al. 2013; Hunt et al. 2014) . One concern, for example, relates to whether the most disadvantaged and vulnerable within communities are engaged in both the action and implementation phases of such studies (Hunt et al. 2014) .
Privacy and confidentiality
Privacy regulations for personal health information in the USA and Canada are described as creating challenges for HPSR data collection (Weisbaum et al. 2005; Anderson et al. 2015) . Threats to participants' anonymity and confidentiality are also described as a feature of HPSR (Dziak et al. 2005) .
Guidance
Thematic analysis of the literature identified general guidance on ethical issues in four main categories: upholding autonomy, identifying and balancing risks and benefits, justice, and determination of ethical review requirements. Here, guidance is defined broadly as encompassing recommendations made by scholars in the ethics literature as well as formal 'guidance' documents. The guidance identified primarily comes from scholarly literature. It largely focuses on obtaining or waiving informed consent ( 
Upholding autonomy
Intervention studies (group and individual level) Guidance relevant to autonomy-related concerns almost exclusively focuses on when and from whom informed consent is ethically required. There is considerable guidance in the literature describing what form of consent is necessary to uphold autonomy in HPSR intervention studies, which is primarily discussed in the context of cluster trials. In cluster trials, consent potentially should occur at each of the two stages of recruitment: (1) consent or permission for the study to proceed-for example, agreement that a particular village can be included (and randomized) within the study and (2) consent to receiving an intervention within the study-for example, individual agreement to receive a particular package of health services.
At the first stage of recruitment, most guidance in the literature suggests relying on 'gatekeepers' may be an acceptable approach to obtaining permission, though Sim and Dawson (2012) , in contrast, call for relying on RECs to determine if a protocol is sufficiently justified to proceed. Given that the gatekeeper approach is commonly discussed in the literature, there exists some guidance regarding how best to carry it out. The Ottawa Statement suggests that selected gatekeepers must have legitimate authority (i.e. their role within the cluster or their organization endows them with the authority to make decisions on behalf of the cluster) that is recognized by cluster members . Osrin et al. (2009) further recommend that, at the minimum, the choice of gatekeeper and the reasons for approaching them be documented.
The need to potentially select multiple gatekeepers for a single study is described (Gallo et al. 2012; Weijer et al. 2012; Hutton 2001) . Osrin et al. (2009, p. 773) report that '[s]ince it is unlikely that one type of person can represent a community, we have sought agreement from a range of stakeholders. In most cases we have held community meetings at which the idea of the trial has been discussed and consent for it sought.' Cluster guardians should sign a consent form that describes their duties before they volunteer a cluster for a trial (Edwards et al. 1999) . They should also only volunteer their cluster when it is in the best interest of the cluster (Gallo et al. 2012) . 5 The SACHRP Recommendations and Ottawa Statement affirm that gatekeeper permission should not substitute for individual informed consent of participants in a cluster trial, or a REC approved waiver of consent, because gatekeepers do not meet the criteria for legitimate proxy consent SACHRP 2014) . Beyond gatekeepers' consent, consultation between researchers and cluster members about the study may help protect group interests in cluster trials (Osrin et al. 2009; Weijer et al. 2012; Taljaard et al. 2013) . In cases where an intervention is sensitive or controversial, cluster consultation may be ethically required in addition to gatekeeper consent (Edwards et al. 1999) . Modes of consultation may include communication with communities through community advisory boards, various media channels, open public forums or meetings with opinion leaders (Taljaard et al. 2013) .
At the second stage of recruitment, individual consent is typically required for all levels of research participants, i.e. those who might be the unit of intervention (sometimes called primary or direct participants) and those from whom data are collected (sometime called secondary or indirect participants) (Edwards et al. 1999; Hutton 2001; Osrin et al 2009; Weijer et al. 2012; Hyder et al. 2014a; Anderson 2015) . The content of consent will also likely vary amongst different levels of research participant (Hutton 2001) .
Guidance in the Ottawa Statement identifies who constitutes research participants in cluster trials. A research participant is defined as an individual: (1) who is the intended recipient of an experimental (or control) intervention, (2) who is the direct target of an experimental (or control) manipulation of his/her environment, (3) with whom an investigator interacts for the purpose of collecting data about that individual or (4) about whom an investigator obtains identifiable private information for the purpose of collecting data about that individual ). The SACHRP Recommendations contain similar guidance.
In studies where the identification and recruitment of participants is not possible before randomization of clusters, participants may be legitimately enrolled following randomization (Mcrae et al. 2011a; Weijer et al. 2012; SACHRP 2014) . Seeking consent after randomization is consistent with the moral purpose of informed consent, as potential participants may still freely choose whether or not to enroll in the trial . When cluster members are approached for consent, the process ought to be tailored to the study arm to which the cluster has been allocated. Recommendations for the content of consent processes for different study arms have been made by Mcrae et al. (2011a,b) . Campbell (2000) notes that, where control groups receive 'usual care', it may not be necessary to obtain their informed consent. However, assuming that the experimental group receives significantly altered care, it is recommended that those randomized to the intervention arm be asked to provide consent (Anderson et al. 2015) . When investigators are recruiting or obtaining consent, they should conduct informed consent in such a way as to limit the potential for coercive influence from cluster or organizational leaders. For instance, consent discussions should be conducted without the presence of cluster or organizational leaders and cluster or organizational leaders should not be informed of the identities of those who agree to or decline study participation ).
Exceptions to individual consent
Certain scholars and the Ottawa Statement take the position that individual consent is not required when a REC is satisfied that conditions for a waiver of consent are met. Proposed conditions for waivers of consent found in the Ottawa Statement include: (1) the research is not feasible without a waiver or alteration of consent 6 and (2) the study interventions and data collection procedures pose no more than minimal risk. Beyond feasibility, it has been suggested that desirability for methodological reasons may be another reason for waiving consent. Sim and Dawson (2012, p. 482 ) state:
It must be argued that individual consent in principle is often feasible but is nonetheless undesirable, or at least dispensable. . . if such consent induces the very contamination that a clusterrandomized trial seeks to avoid, or leads to the recruitment of an unrepresentative sample.
However, while the Ottawa Statement defines minimal risk as the 'risks of daily life', it remains somewhat unclear how this is to be interpreted in the broader context of HPSR, which introduces a range of potentially unconventional risks (Table 3) . As a possible alternative to the minimal risk construct, Hyder et al. (2014b) have proposed relying on a different type of assessment to determine if individual consent can be waived. They suggest that what might be considered is whether a study intervention alters the local environment in a way that patients or citizens would normally be consulted about prior to implementation. In doing so, local social and political norms and the degree of trust in health systems and other social institutions should be considered in order to reduce potential for the consent strategy to further legitimize and entrench norms that relate to a lack of transparency (Hyder et al. 2014b ). Sim and Dawson (2012) raise similar considerations, noting that, in the everyday health care arena, individual consent is not normally considered necessary for health care interventions that are implemented at a community or practice level. This state of affairs reflects an acceptance that such measures are often legitimately decided at a managerial level and that the same degree of consent is not expected.
The guidance on whether informed consent is required for QI activities is divided, with three positions being taken or described: (1) there is not necessarily a need for informed consent but patients should be informed about QI activities (Cassell and Young 2002; Hakama et al. 2012; Platt et al. 2014) , (2) informed consent is necessary for QI activities that involve significant burdens or risks beyond what patients would normally experience (Fox and Tulsky 2005; Tapp et al. 2010; Kass and Pronovost 2011; Faden et al. 2013a,b) and (3) informed consent is necessary for all QI activities (Horsfall and Cleary 2002) .
In cases in which a waiver of consent has been granted, it is recommended that researchers and institutions inform the study population that the study is taking place and make information about the study available to the eligible study population Anderson et al. 2015) . This might occur, for example, via distribution of leaflets, poster placement in locations such as schools or physicians' offices, or public health bulletins. Information should still be provided even if the member of the study population does not have access to a feasible alternative intervention and/or cannot practicably withdraw. Failure to provide this information risks psychological harm, as subsequent discovery of inclusion in an experiment might result in a sense of violation (Hutton 2001 ).
Identifying and balancing risks and benefits
Limited guidance on balancing risks and benefits in HPSR is described in the literature. Three main suggestions are made. First, the risks and benefits associated with a particular study must be identified and assessed for all levels of research participants, for the health system, and for vulnerable individuals and groups SACHRP 2014; Hyder et al. 2014a) . Second, identified risks associated with data collection should be minimized Hunt et al. 2014) . Third, identified risks must stand in reasonable relation to the knowledge to be gained or the benefits of the study Hyder et al. 2014a) .
When assessing risks and benefits, the literature emphasizes considering risks beyond medical harms such as social and cultural risks (Table 3 ). Multiple authors recommend that RECs review the risks and benefits of QI proposals only in regard to the portion of the protocol that is new or different from conventional practice. Several suggestions have been put forward about how researchers might go about identifying the unintended consequences associated with their studies (Table 2 ) (Daly and Rosenfeld 2003; Molyneux et al. 2009; Weijer et al. 2012) . Strategies to minimize certain risks in HPSR are described and are also summarized in Table 2 . Molyneux et al. (2009) and Hyder et al. (2014a) further recommend employing a monitoring system during research so that harms across multiple health system components and stakeholders are captured.
Very little guidance exists on what constitutes an acceptable balance of risks and benefits in HPSR. At the cluster level, it was argued that studies should be in the best interests of a cluster as a whole, i.e. the expected utility associated with the study should outweigh the alternative (status quo) (Edwards et al. 1999) . However, it is unclear how group interests or utility can be quantified. The Ottawa Statement suggests that benefits and harms to vulnerable participants (individuals and groups) must be acceptable but provides little information on what 'acceptable' means.
Justice
HPSR and social justice Scholars argue that funders and researchers have an obligation to support and conduct HPSR that contributes to the reduction of health disparities between and within countries (Faden et al. 2013b; Pratt and Hyder 2015b) . Towards fulfilling such obligations, an ethics framework proposed by Faden et al. (2013b) requires that learning activities-inclusive of activities intended to improve the practice, value, quality, or efficiency of healthcare institutions and systems-be assessed to determine whether they perpetuate or exacerbate unjust inequalities and whether they can be structured to advance the goal of reducing or eliminating inequalities and discrimination in health care.
Another framework proposed by Pratt and Hyder (2015b) suggests that equity-oriented HPSR projects should have four main features-a focus on worst-off or disadvantaged populations within host countries, research questions related to equal access and equitable financing of health systems, development of LMIC institutions and researchers' capacity to conduct HPSR independently and promotion of research translation that benefits the worst-off (Pratt and Hyder 2015b) .
Fair subject selection Very little guidance exists on what constitutes fair subject selection in HPSR. Khanlou and Peter (2005) recommend that all members of a community should be given meaningful opportunities to participate, especially if they have been under-represented in the past such as members of vulnerable and marginalized groups.
Responsiveness
Very little guidance exists on what responsiveness entails in HPSR. Pratt and Hyder (2015c) propose that the concept of responsiveness should be reinterpreted as responsiveness to system needs, where national health system performance assessments can be relied upon to identify system needs and/or responsiveness to system priorities, which entails aligning research with HPSR priorities set through a country-owned process involving national and sub-national policymakers from host countries. Khanlou and Peter (2005) argue that the goal of participatory action research should be to empower vulnerable populations to address the determinants of health. Ethics review should, therefore, consider whether the community participated in identifying the research topic and whether community members are adequately enabled to contribute to the research.
Standard of care
The limited guidance available presents three main perspectives on what is ethically acceptable to provide control groups during HPSR: (1) no care or the local de facto standard, 7 (2) the local de jure standard 8 or (3) relying on equipoise to settle the matter (Kukla 2007; Binik et al. 2011; Weijer et al. 2012) . Kukla (2007) argues that researchers should not knowingly offer research participants care that is inferior to that which they would be morally entitled to receive outside of the study (i.e. the local de jure standard), given local material, economic and cultural conditions. Binik et al. (2011, p. 118) contend that 'the control group does not receive substandard (WHO 2013; Hyder et al. 2014a; Macklin 2014) Costs to health system (increased workload for staff; vertical programs weaken health systems; waste of resources; overwhelmed supply side) (Hyder et al. 2014b; Thomson et al. 2014 ) Psychological distress during collection of sensitive information (Chaney et al. 2008; Molyneux et al. 2009; WHO 2013) Reputational or financial harm to groups or health institutions (WHO 2013; Hyder et al. 2014a ) Medical/physical harm (WHO 2013 Macklin 2014) Distortion of local markets (Hyder et al. 2014a ) Opportunity costs to participants for time spent participating in HPSR (e.g. loss of income) (Molyneux et al. 2009) Widening of health inequalities or further marginalization of disadvantaged groups (Lange 2014; Thomson et al. 2014 ) Weakened intrinsic motivation and diminished well-being (Thomson et al. 2014) Socio-political instability, social discord (Hill 2004; Khanlou and Peter 2005; Osrin et al 2009; Hunt et al. 2014 ) Negative effect on relationships with others (such as doctor-patient relationship) (Thomson et al. 2010) Lack of intervention sustainability (London et al. 2012; Hyder et al. 2014b ) Privacy (improper disclosure of health information) (Horsfall and Cleary 2002; Chaney et al. 2008; Faden et al. 2013a; Macklin 2014) External actors foist ill-conceived policy measures on LMICs (Buse 2008) treatment as long as there is disagreement among the community of expert practitioners about whether the experimental or control intervention is preferable'. Commentators also suggest that some ethical concerns about the treatment of control group members may be resolved by using a stepped wedge design, in which an intervention is provided sequentially to individual participants or clusters. This proposal rests on the premise that the ethical requirement to balance harms and benefits of participation is met as long as research participants are provided with the experimental agent at some point during the trial or after its completion. However, Binik et al. (2011) and Osrin et al. (2009) argue against this option, asserting that a delayed implementation design strategy raises both practical and conceptual difficulties.
Ancillary care
Olson (2014) recommends using existing frameworks such as the duty-of-rescue framework 9 or the partial entrustment model 10 to identify what ancillary care researchers are ethically obligated to provide to participants in HPSR. However, in doing so, researchers should take both individual and health system needs into account (Olson 2014) . Thus, ancillary care provision may entail health system strengthening activities.
Post-study commitments
Very little guidance exists on what is owed post-study in HPSR. There is emphasis on a need to disseminate research findings and make agreements to do so early on (Horsfall and Cleary 2002; Weisbaum et al. 2005; Khanlou and Peter 2005; Tapp et al. 2010; Platt et al. 2014 ), but it is less clear to whom researchers are ethically obligated to disseminate their findings and what researchers should do to support research uptake. Hunt et al. (2014) suggests that researchers have an obligation to influence policy and practice beyond the research setting. They recommend that study results should travel back through these concentric circles -from village, to region, to nation, in order to influence policy setting and allow sustainability of the model and scale-up nationally. . . Researchers must be "politically astute" in order to navigate these processes and to promote the likelihood that research outcomes will contribute to social value through integration in policy setting measures. (Hunt et al. 2014, p. 13) Sustainability Implementation research should be performed in partnership with non-research personnel to promote intervention sustainability poststudy. Dowdy (2006) recommends including non-research personnel in not only study design but also study execution in order to enhance likelihood of local actors continuing to implement the study intervention after HPSR ends.
Determination of ethical review requirements
Distinguishing QI from research We found no comprehensive guidance to support ethics committees in determining whether and how to review HPSR in general. However, scholars have proposed various criteria that signal when a QI activity might warrant ethics committee review and approval. Given the overlap of HPSR and QI, it is informative to consider criteria commonly used to distinguish QI from 'research.' A QI activity that presents some or all of the following features, it is argued, should likely be treated as 'research' and be subject to relevant research oversight requirements: (1) having a primary aim of creating generalizable knowledge, (2) intent to publish in a peer-reviewed journal, (3) using research methods to collect (new) data, (4) involving a change in clinical practice that involves some element of risk for patients, (5) being conducted by a person who would not normally have access to patient records, (6) gathering information beyond what is gathered in routine clinical care and/or (7) involving randomization or use of placebo (Daly and Rosenfeld 2003; Fox and Tulsky 2005; Driscoll et al. 2008; Nerenz 2009; Hakama et al. 2012; WHO 2013) .
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A consensus statement on the matter was published in 2007, convening many of the scholars who had previously published on the topic, along with representatives of national organizations in the USA involved in funding or conducting clinical research (Lynn et al. 2007) . The consensus statement affirmed that most QI is not research, as defined by the Common Rule in the USA and is, therefore, not subject to requirements for REC review and written informed consent, although it may be subject to other forms of independent oversight and approval. Where activities have both QI and research aims, the consensus statement contends that they should be treated as research (Nerenz 2009 ).
The Ottawa Statement recognizes that some QI initiatives seeking solely to improve local service delivery are (generally) not research and may not require review, but it suggests that most cluster randomized trials are designed to produce generalizable knowledge. As such, it recommends QI activities using cluster trial methods undergo ethics review. Expedited review is recommended for low-risk studies that do not include vulnerable populations. Where cluster randomized trials pose substantial risk or involve vulnerable participants, they ought to receive intensive scrutiny .
A number of criteria have been proposed as being relevant to determining whether QI activities (that are deemed not to be research) should still be subject to some form of ethical review: level of risk, methods employed, whether the activities are prospective or retrospective and whether vulnerable participants are involved (Fox and Tulsky 2005; Daly and Rosenfeld 2003; Tapp et al. 2010; WHO 2013) . For example, given the absence of subject burden (e.g. opportunity costs related to participation in prospective research) associated with retrospective record reviews and the minimal risk of privacy intrusions, Daly and Rosenfeld (2003) conclude that ethical review is not warranted for QI activities involving retrospective record reviews. Van Teijlingen et al. (2008) extend this to recommend that non-invasive, observational studies, which may include collecting data prospectively through interviews or postal questionnaires, be given a waiver or 'light touch' review. However, others support the view that QI activities should not require any sort of ethics review (Infectious Diseases Society of America 2009).
Suggestions for what ethical review for QI (deemed not to be research) might entail and who should perform it have also been put forward. Kass and Pronovost (2011) suggest relying on an independent third-party entity with appropriate expertise to scrutinize QI activities. Some institutions may give review authority to RECs (WHO 2013). In any case, the group should include individuals familiar with QI methods and individuals familiar with ethical standards (Fox and Tulsky 2005) . In terms of the content of this review, Faden et al. (2013b) have proposed a normative framework to guide oversight of 'learning health care activities,' which includes QI. 12 The framework has thus far not been translated into guidelines for ethics review.
M&E and ethical review
A small number of articles recommend that M&E activities related to health systems should be subject to ethical review where the risks involved are deemed high (Hill 2004; Hyder et al. 2014b ).
Other issues
Community engagement Very limited guidance on community engagement in HPSR is described in the literature. However, this guidance does suggest some form of community or patient engagement may be ethically required as part of HPSR, including where participatory action research or cluster trial methods are used and where QI activities are undertaken (Davison et al. 2013; Weijer et al. 2012; Wilfond 2013 ).
Privacy and confidentiality
Where electronic medical records or administrative data sources are used, data analysis should make use of anonymous or 'de-linked' data whenever possible. This de-identification should occur prior to data reaching the researcher for analysis (Fox and Tulsky 2005; Weijer et al. 2012) .
The literature emphasizes that researchers should receive formal training on their organizations' privacy principles and requirements and should agree, as a matter of record, to respect those policies (Fox and Tulsky 2005; Horsfall and Cleary 2002; WHO 2013) . Privacy officers should be employed to handle all requests for guidance on information privacy. These officers can also ensure that the codes for linked data are maintained securely and that de-linked data are rendered anonymous before they are released (Fox and Tulsky 2005; Horsfall and Cleary 2002) . Development of privacy codes and privacy assessments will further facilitate a harmonized approach to protecting privacy in HPSR (Weisbaum et al. 2005) .
Relational ethics and participatory action research
The small amount of literature on participatory action HPSR emphasizes that the ethical considerations faced in such work are best addressed by a 'relational ethics' framework (Davison et al. 2013) . Hunt et al. (2014) call for further exploration of the relational ethics of participatory action HPSR.
Discussion
This scoping review identified a broad range of ethical issues spanning four main categories-upholding autonomy, identifying and balancing risks and benefits, justice and determination of ethical review requirements. The review indicates that the ethical values behind HPSR place an emphasis on its generating population health benefits and contributing to the reduction of health disparities. Unsurprisingly then, numerous ethical considerations and concerns relating to beneficence and justice arise in HPSR. However, available guidance, which primarily comes from the bioethics literature rather than official guidance documents, focuses mainly on informed consent and cluster trial methodology.
The results of the scoping review demonstrate three significant issues for HPSR ethics. First, since the field of HPSR is young, evolving, and often not well described (until recently), an exploration of ethical issues arising in HPSR is also relatively recent. Second, while there is some literature on ethical issues in HSPR, it is not reflective of the breadth or depth of potential ethical issues or comparable to the volume and quality of ethics scholarship done in other fields such as clinical research. Some ethical issues relating to particular features of HPSR were not strongly discussed in the literature; for example, ethical issues associated with adaptive designs-where HPSR methods or interventions change during the course of studies in response to real-world conditions. HPSR often uses social science methods including case study and ethnography, which are grounded in a constructivist or relativist epistemology. Yet, existing guidance for HPSR focuses primarily on cluster trials, which emerged from within a positivist tradition of biomedical research. The use of social science methods in HPSR may require guidance that is more flexible and aligns better with research that allows for multiple realities and experiences to coexist, rather than one objective reality. In addition, the literature identified by the review did not adequately consider the ethical issues related to the policy dimensions of HPSR. It did not discuss what issues arise due to blurred boundaries between health policy research and policymaking, the risks related to using evidence for policy, the pressure for rapid scale up of research evidence into policy, or HPSR studies emerging alongside governmentenacted reforms or interventions. In such cases, research teams may have little to no control over the nature of interventions or the selection of research populations. These gaps in the literature need to be addressed.
Third, even though ethical issues are being recognized, there is a stark lack of guidance for researchers and ethics committees on HPSR of all types. This presents a specific challenge to the current conduct and ethical review of HPSR. Systematic approaches and criteria for ethics committee review of HPSR were not identified in the formal or informal literature. In order to be able to move meaningfully towards the future development of ethics guidance for HPSR, additional research and scholarship is needed on priority areas, which are summarized in Box 1.
Scholarship in these priority areas will require further consideration of which ethical issues identified by the review are in fact unique to HPSR. Where the review has identified gaps in guidance, there may be existing pertinent guidance for ethical issues that arise both in HPSR and, for instance, in social science research. Some ethical issues may also arise due to the use of specific methodologies. In such cases, it would be valuable to survey additional ethics literature and guidance on particular methods (e.g. participatory action research), which may contain valuable guidance that can be applied or adapted for HPSR.
Where guidance exists, the literature suggests little consensus for many of the HPSR ethics issues discussed. One of the more recent and controversial areas involves identifying when HPSR meets formal definitions of 'research' and whether the research/non-research distinction should matter from an ethics perspective. Related areas of inquiry (e.g. QI) have relied on such distinctions to differentiate various learning activities from research and establish parallel norms for oversight (in some instances). However, such distinctions largely emerged from clinical care and biomedical research settings. Efforts to distinguish learning activities specifically from HPSR and to differentiate policymaking processes from health policy research are less discussed.
Fifth, the importance of normative work to identify the core ethical principles and values that should guide HPSR is again emphasized. Agreed upon core principles and values should inform the development of much-needed ethical guidance for the field. Thus far, they have largely not been proposed or debated, which must occur before it is possible to develop a meaningful consensus on ethics-related HPSR norms. The ethical concerns documented as part of the scoping review suggest that traditional biomedical principles of autonomy, beneficence and justice likely apply to HPSR. However, it may be appropriate to interpret the principle of justice more expansively for HPSR. Upholding justice in HPSR may require both achieving a fair balance of burdens and benefits in individual projects and advancing health and social justice. Additional principles such as sustainability may also be pertinent for HPSR ethics. Further work to capture the breadth and depth of potential ethics issues in HPSR will likely speak to the possible relevance of other ethical principles.
It also remains unclear who bears responsibility for addressing particular ethical issues identified by this review. For example, parties other than RECs may be more capable of ensuring that national research priority-setting processes are not exclusively donor-driven or that proposed research helps reduce health disparities. The responsibilities of other stakeholders such as research institutions, funders and policymakers to address the ethical issues raised in this paper need to be investigated.
Finally, the literature identified by the review was largely written by high-income country authors and/or focused on the high-income country context. Discussions relating to high-income country regulatory constructs and normative frameworks were dominant. This perhaps, in part, reflects the developing nature of ethics and regulatory oversight capacities in many LMICs. Further empirical work is recommended to capture LMIC researchers' experiences and future scholarship on HPSR ethics by bioethicists from LMICs is strongly encouraged.
The review had two main limitations. First, it is possible that the search strategy failed to identify some relevant literature because that literature used terms for HPSR that are uncommon and were not picked up by the search strategy. Ethical issues arising in HPSR may also be described in literature using more specialized terms than those used in this review's search strategy. For example, while our search returned very little guidance with respect to the specific challenge of minimizing the risk of diminishing intrinsic motivation during health incentive research, there is literature addressing intrinsic motivation that may have been returned with more specific search terms related to behavioral research. Given that the range of HPSR ethics issues described in the literature were not known prior to the search, it was not possible to ensure that all issues around which one might want guidance were included in the search terms. Our search strategy was, however, reviewed by health systems researchers, ethics experts and information specialists prior to implementation. Second, the coding process was performed by two single coders who each coded a subset of the 107 documents, rather than by two coders who each thematically analyzed all 107 documents. However, the accuracy of coded segments was checked by the project manager for 100% of text.
Conclusion
This scoping review constitutes the most comprehensive report of the HPSR ethics literature to-date. Given that it presents an overview of the ethical issues that arise during HPSR and the available guidance on these issues, it can serve as a rich resource for researchers, RECs, research institutions, professional associations and funders.
changes to or removal of some of the standard elements of disclosure in the informed consent-for example, to maintain blinding in the case of a behavioural intervention . 7. The local de facto standard is the standard of care set by what physicians in a locality actually do in practice (London 2000) . 8. The local de jure standard is the standard of care that is set, not by what physicians in the locality actually do, but by the judgement of medical experts in the host country as to what diagnostic and therapeutic practices have proved most effective against the illness in question, under the present material conditions (London 2000) . 9. The duty of rescue is derived from a moral principle affirming that we ought to help people who are in need and whom no one else is well-situated to help, provided that we can do so without our incurring serious sacrifice or risk (Belsky and Richardson 2004) . A two-step approach has been developed to help identify researchers' minimum ancillary care obligations as required by the general duty of rescue (Merritt et al. 2010) . 10. According to this model, researchers may be obligated by special duties to provide ancillary care for certain health needs that fall within the scope of entrustment. Research participants implicitly entrust certain aspects of their health into researchers' care by granting informed consent for study procedures. For those health conditions that are within the scope of entrustment, the second step in using the partial-entrustment model is to assess the strength of the researchers' special duty to provide ancillary care (Belsky and Richardson 2004) . 11. The World Health Organization (2013) further recommends that patient safety activities be considered 'research' when they are aimed at addressing a specific question, they use a predefined approach or method for collecting data in response to the question and their findings are intended to be applied to settings beyond those in which the activity or program is implemented. 12. It should be noted that this ethical framework applies to all learning health care activities, both those that might be classified as research and those that would not be, because (Faden et al. 2013b ) argue that such a distinction is no longer helpful. Brody and Miller (2013) argue against that contention.
